Accéder au contenu
Merck
Toutes les photos(1)

Documents

SML2304

Sigma-Aldrich

Clozapine N-oxide hydrochloride

≥98% (HPLC), powder, muscarinic DREADD activator

Synonyme(s) :

Clozapine N-oxide hydrochloride, 8-Chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo[b,e](1,4)diazepine N-oxide, hydrochloride salt

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C18H19ClN4O · xHCl
Numéro CAS:
34233-69-7
Poids moléculaire :
342.82 (free base basis)
Code UNSPSC :
12352119
Nomenclature NACRES :
NA.77

product name

Clozapine N-oxide hydrochloride, ≥98% (HPLC), Water soluble Clozapine N-oxide

Source biologique

synthetic

Pureté

≥98% (HPLC)

Forme

powder

Conditions de stockage

desiccated

Solubilité

DMSO: 40 mg/mL
water: 40 mg/mL

Conditions d'expédition

ambient

Température de stockage

2-8°C

Chaîne SMILES 

ClC1=CC2=C(NC(C=CC=C3)=C3C(N4CC[N+]([O-])(C)CC4)=N2)C=C1.[xHCl]

InChI

1S/C18H19ClN4O/c1-23(24)10-8-22(9-11-23)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3

Clé InChI

OGUCZBIQSYYWEF-UHFFFAOYSA-N

Description générale

Clozapine N-oxide hydrochloride is a water soluble form of Clozapine N-oxide (CNO) (Sigma cat# C0832). CNO is a pharmacologically inert metabolite of the atypical anti-psychotic drug clozapine. CNO is a ligand for the engineered Gq protein coupled receptors (GPCRs) in the chemogenetic Designer Receptors Exclusively Activated by Designer Drug (DREADD). The typical use of DREADD is testing, enhancing neuronal firing and activating Gq signaling in neuronal and non-neuronal cells.

The selective targeting of DREADD systems to cell population can be achieved by using a cell type-specific promoter to drive DREADD expression, and the expression of this promoter can be further controlled using a recombinase-based system. DREADDs possess a low affinity for endogenous ligands and little constitutive activity, but may be activated by synthetic compounds such as CNO.

DREADD systems are activated by low nM concentrations of CNO and mobilize intracellular calcium. CNO appears to be pharmacologically and behaviorally inert in mice and rats when administered at the recommended doses (generally 0.1–3 mg/kg). CNO is commonly administrated via injection but also can be mixed into food chow or drinking water.

Autres remarques

High concentration Solutions of (40mg/ml) can be prepared from the water soluble CNO and be used in CNO applications without the use of DMSO.

Pictogrammes

Skull and crossbones
GHS06

Mention d'avertissement

Danger

Mentions de danger

H301,H336

Classification des risques

Acute Tox. 3 Oral - STOT SE 3

Organes cibles

Central nervous system

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Masaki Ishikawa et al.
The FEBS journal, 291(5), 945-964 (2023-12-01)
Indoleamine 2,3-dioxygenase 2 (IDO2) is an enzyme of the tryptophan-kynurenine pathway that is constitutively expressed in the brain. To provide insight into the physiological role of IDO2 in the brain, behavioral and neurochemical analyses in IDO2 knockout (KO) mice were
Susan M Ferguson et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 33(28), 11668-11676 (2013-07-12)
The dorsal striatum has been implicated in reward-based decision making, but the role played by specific striatal circuits in these processes is essentially unknown. Using cell phenotype-specific viral vectors to express engineered G-protein-coupled DREADD (designer receptors exclusively activated by designer
Blaine N Armbruster et al.
Proceedings of the National Academy of Sciences of the United States of America, 104(12), 5163-5168 (2007-03-16)
We evolved muscarinic receptors in yeast to generate a family of G protein-coupled receptors (GPCRs) that are activated solely by a pharmacologically inert drug-like and bioavailable compound (clozapine-N-oxide). Subsequent screening in human cell lines facilitated the creation of a family
Georgia M Alexander et al.
Neuron, 63(1), 27-39 (2009-07-18)
Examining the behavioral consequences of selective CNS neuronal activation is a powerful tool for elucidating mammalian brain function in health and disease. Newly developed genetic, pharmacological, and optical tools allow activation of neurons with exquisite spatiotemporal resolution; however, the inaccessibility
Jean-Marc Guettier et al.
Proceedings of the National Academy of Sciences of the United States of America, 106(45), 19197-19202 (2009-10-28)
Impaired functioning of pancreatic beta cells is a key hallmark of type 2 diabetes. beta cell function is modulated by the actions of different classes of heterotrimeric G proteins. The functional consequences of activating specific beta cell G protein signaling
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique